Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...4142434445464748495051...123124»
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Journal:  Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. (Pubmed Central) -  Dec 18, 2022   
    Our study did not identify any meaningful difference in OS between atezolizumab plus bevacizumab and lenvatinib. Although some hints are provided suggesting that patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease might benefit more from lenvatinib therapy and patients with viral aetiology more from atezolizumab plus bevacizumab.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Systemic Therapy in Intermediate-Stage HCC (2F Room 201ABC) -  Dec 18, 2022 - Abstract #APASL2023APASL_281;    
    Atezo/bev was used to achieve tumor shrinkage, while lenvatinib was used to reduce the tumor blood flow and necrosis. Therefore, there are several treatment option in treatment strategy of intermediate-stage HCC.
  • ||||||||||  Systemic Therapy for HCC: From Guidelines to the Real World (Western Perspective) (2F Room 201ABC) -  Dec 18, 2022 - Abstract #APASL2023APASL_279;    
    Conversely, there is no evidence supporting one tyrosine kinase inhibitor (TKI) over the others (including cabozantinib or regorafenib) when patients progress or do not tolerate immunotherapy...Yet, this should not be taken as an argument against the usefulness of guidelines. On the contrary, in the presence of limited availability of resources it is even more important to consider the scientific evidence supporting a given therapeutic strategy and avoid those opinions based on personal experience or other sources of knowledge
  • ||||||||||  Systemic Therapy for HCC: From Guidelines to the Real World (Asian Perspective) (2F Room 201ABC) -  Dec 18, 2022 - Abstract #APASL2023APASL_278;    
    Multi-kinase inhibitor (MKI) including sorafenib or lenvatinib is reserved for patients who are contraindicated for IO...Consequently, subsequent treatment after front-line IO based combination treatment would be more complex and diverse among countries or regions, and locoregional treatment is still a key treatment of option for advanced HCC in Asia. Although that IO combination therapy replaces MKI is ongoing worldwide, the treatment consideration would be somewhat different between Western and Asian.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Nobel Treatment Strategy in Intermediate-Stage HCC (Plenary Hall) -  Dec 18, 2022 - Abstract #APASL2023APASL_195;    
    Atezo/bev was used to achieve tumor shrinkage, while lenvatinib was used to reduce the tumor blood flow and necrosis. Therefore, there are novel treatment option in treatment strategy of intermediate-stage HCC.
  • ||||||||||  Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Preclinical, Review, Journal, IO biomarker:  Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research. (Pubmed Central) -  Dec 17, 2022   
    In the last decade, relevant advances have occurred in the treatment of hepatocellular carcinoma (HCC), with novel drugs entering the clinical practice, among which tyrosine kinase inhibitors (TKIs) such as lenvatinib, cabozantinib and regorafenib, and immune checkpoint inhibitors (ICPIs) either alone or in combination with VEGF inhibitors...To this aim, we will mainly focus on two issues: (i) HCC models informative on NAFLD-NASH HCC and (ii) HCC models helping to elucidate mechanisms underneath immunotherapy. We have chosen these two settings since they represent, respectively, the most rapidly arising cause of chronic liver disease (CLD) and HCC in western countries and the most promising therapeutic option for advanced HCC.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial primary completion date:  Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (clinicaltrials.gov) -  Dec 15, 2022   
    P2,  N=60, Active, not recruiting, 
    This study has been registered on the PROSPERO database with the registration number CRD42021286575. Trial primary completion date: Oct 2022 --> Oct 2023
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide population. (Available On Demand; Poster Board No. E11) -  Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_469;    
    Our study did not identify any meaningful difference in overall survival between atezolizumab plus bevacizumab and lenvatinib. Although some hints are provided suggesting that patients with NASH/NAFLD might benefit more from lenvatinib therapy and patients with viral etiology more from atezolizumab plus bevacizumab.
  • ||||||||||  Efficacy and safety of frontline systemic therapy for advanced hepatocellular carcinoma (aHCC): A network meta-analysis of landmark phase III trials. (Available On Demand; Poster Board No. D1) -  Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_439;    
    These tested respectively: sorafenib (S) vs placebo (SHARP and Asia Pacific), sunitinib (Sun) vs S, brivanib (Bri) vs S, linifanib (Lin) vs S, lenvatinib (L) vs S, nivolumab (Nivo) vs S, atezolizumab+bevacizumab (A+B) vs S, sintilimab+IBI-305 vs S, durvalumab+tremelimumab (D+T) vs S, atezolizumab+cabozantinib (A+C) vs S, donafenib vs S, camrelizumab plus rivoceranib (C+R) vs S, pembrolizumab plus lenvatinib (P+L) vs L, and tislelizumab (TS) vs S as first line treatments for aHCC... Combination of ICI + anti-VEGF antibodies leads to the greatest OS benefit compared to sorafenib, whereas ICI + kinase inhibitor regimens are associated with greater PFS benefit at the cost of higher toxicity rates.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice. (Available On Demand; Poster Board No. B2) -  Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_402;    
    This was an open-label, multicenter, prospective study that enrolled patients who had advanced HCC with C-P A or B, treated with lenvatinib as first-line or second-line after atezolizumab plus bevacizumab (Atz + Bv) at 10 sites in Japan... Lenvatinib is expected to be safe and effective in patients with advanced HCC who have a high tumor burden and second-line treatment after Atz + Bv, whereas liver function was maintained with C-P A. However, in C-P B, this study found lower efficacy and higher discontinuation rates due to AE compared with C-P A. Clinical trial information: s031190017.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Outcome of receiving lenvatinib following immunotherapy in patients with advanced hepatocellular carcinoma. (Available On Demand; Poster Board No. A17) -  Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_397;    
    We found that median OS was 13 months in patients who received lenvatinib after immunotherapy which is comparable to survival in other studies when used as first line therapy. Our experience demonstrates that patients may benefit from treatment with lenvatinib following initial progression on immunotherapy.
  • ||||||||||  Review, Journal:  New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations. (Pubmed Central) -  Dec 12, 2022   
    Recently, other immunotherapy-based combinations (durvalumab-tremelimumab, lenvatinib-pembrolizumab, cabozantinib-atezolizumab, and camrelizumab-rivoceranib) reported results in phase III studies, and might challenge this new standard of care...We will then present the different recommendations about second-line treatment following the first-line immunotherapy-based combination, discussing the rationale for the differences in existing recommendations. We will finally discuss the challenges for future drug development in advanced HCC.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Combination of Bone-Modifying Agents with Immunotarget Therapy for Hepatocellular Carcinoma with Bone Metastases. (Pubmed Central) -  Dec 12, 2022   
    A total of 21 (33.9%) patients received TKIs (Sorafenib or Lenvatinib) alone and 41 (66.1%) received TKIs + ICIs...Prolonged OS (33 months vs. 16 months; p = 0.0048) and PFS (33 months vs. 11 months; p = 0.0027) were observed in patients with long-term use of BMAs compared with no or perioperative use of BMAs. The TKIs + ICIs combination and long-term adjuvant of BMAs may offer a survival advantage for HCC patients with BoM without severe adverse events, which requires further validations.
  • ||||||||||  Retrospective data, Review, Journal:  First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis. (Pubmed Central) -  Dec 11, 2022   
    The TKIs + ICIs combination and long-term adjuvant of BMAs may offer a survival advantage for HCC patients with BoM without severe adverse events, which requires further validations. The combination of ICB with TKI such as pembrolizumab plus lenvatinib needs to be considered over monotherapy in the elderly population, but further validation using real-world data or prospective trials is necessary to confirm the efficacy and safety of first-line regimens for the geriatric population with advanced RCC.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal:  The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma. (Pubmed Central) -  Dec 10, 2022   
    P2
    After EMA approval, pembrolizumab plus lenvatinib represents the new standard second-line treatment in endometrial cancer patients, regardless MMR status. Further studies are investigating the role of ICIs and TKIs in the first line and are testing new combinations (e.g. ICIs plus PARP inhibitors).
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Journal, PD(L)-1 Biomarker, IO biomarker:  An overview: Management of patients with advanced hepatocellular carcinoma. (Pubmed Central) -  Dec 9, 2022   
    In addition, many therapies other than tyrosine kinase inhibitors that might have additional survival benefits when combined with other therapeutic modalities, including immunotherapy, transarterial chemoembolization, radiofrequency ablation, hepatectomy, and chemotherapy, have also been examined. This review provides an overview on the current understanding of disease management and summarizes current challenges with and future perspectives on advanced HCC.
  • ||||||||||  Review, Journal, PD(L)-1 Biomarker:  Optimization of first-line systemic therapy in patients with advanced clear cell renal cell carcinoma. (Pubmed Central) -  Dec 9, 2022   
    Although five immune-oncologic-drug-based combination therapies, such as ipilimumab plus nivolumab, avelumab plus axitinib, pembrolizumab plus axitinib, nivolumab plus cabozantinib, and pembrolizumab plus lenvatinib, have been approved for advanced renal cell carcinoma (RCC) in Japan, the optimal therapy for advanced RCC has not been determined...Moreover, novel drugs, such as the hypoxia-inducible factor 2a inhibitor (belzutifan) or immunostimulatory interleukin-2 cytokine prodrug (bempegaldesleukin) have been developed, and phase 3 clinical trials of combination therapy using these drugs for treatment-naïve advanced RCC are ongoing. Further development of systemic therapies for advanced RCC is required.